A special division of ICAN, International Cancer Advocacy Network
Welcome to the support group for patients diagnosed with PDL1 (CD274) Amplification!
If your tumor is PDL1 amplified (PDL1 is also known as CD274; PDL1 and CD274 are the same gene), it means you have had a Next Generation Sequencing (NGS) report (also referred to as comprehensive biomarker testing or molecular profiling) that has found the PDL1 gene to be "amplified." You thus, have more copies of that gene than is normal.
So if you are PDL1 amplified, you have come to the right place.
We are a multi-stakeholder patient-focused organization featuring fellow PDL1 amplified patients, their care partners, and medical oncologists interested in this important gene amplification.
We are thrilled to have Razelle Kurzrock, MD as Honorary Chair of the PDL1 Amplifieds!
If your cancer is PDL1 amplified, you may well be a candidate for immune checkpoint blockade--the immunotherapies you hear about all the time--KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), TECENTRIQ (atezolizumab), IMFINZI (durvalumab), BAVENCIO (avelumab), LIBTAYO (cemiplimab), and many more such drugs in the pipeline.
Why is Next-Generation Sequencing (NGS) critically important to identify PDL1 amplifications?
In a small study, nearly 70% of patients with end-stage, treatment refractory solid tumors with PDL1 amplification "had objective responses after checkpoint blockade administration." The longest responder remains in complete remission at 6.5 years.
PDL1 amplification has been identified in more than 100 different solid tumor types.
Some of the tumor types that have been shown to be PDL1 amplified are listed below; however, a small subset of virtually any tumor type can have PDL1 amplification:
THERE IS ALSO AN NCI-SWOG NATIONAL TRIAL—CALLED "DART"— FOR IMMUNOTHERAPY OF RARE CANCERS THAT INCLUDES A PDL1 AMPLIFIED COHORT.
Clinical Trial: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ClinicalTrials.gov Identifier: NCT02834013
Please contact S1609SC@swog.org for questions regarding the trial.
Since ICAN and the PDL1 Amplifieds strictly adhere to all HIPAA (Health Insurance Portability and Accountability Act of 1996) provisions to protect your privacy, during our initial intake call/meeting with you, we will review, and you will have a chance to discuss with us our Navigation Consent forms.
PDL1 Amplified (https://pdl1amplified.org) is a special division of
ICAN, International Cancer Advocacy Network.
*Marcia K. Horn is President and CEO of ICAN International Cancer Advocacy Network and
Executive Director of the Exon 20 Group and PDL1 Amplified.